Canada: AstraZeneca’s LOSEC Patent Valid And Infringed By Apotex

Last Updated: March 18 2015
Article by Mark Biernacki

On March 16, 2015, following a 40-day trial in 2014, Justice Barnes of the Federal Court issued a 175-page decision finding certain claims of Canadian Patent No 1,292,693 ("'693 Patent") valid and infringed by Apotex's manufacture, promotion and sale of Apo-Omeprazole capsules in Canada and elsewhere: AstraZeneca Canada Inc et al v Apotex Inc, 2015 FC 322. A separate reference will determine the quantum of Apotex's liability. This reference will be heard together with the reference to quantify AstraZeneca's liability, if any, following the finding of s. 8 liability in Apotex Inc v AstraZeneca Canada Inc, 2012 FC 559, aff'd 2013 FCA 77. One of the issues for determination will be the impact of the infringement finding on any s. 8 liability.

AstraZeneca was represented by a trial team from Smart & Biggar, comprised of Gunars Gaikis, Nancy Pei, Mark Biernacki, Lynn Ing, Junyi Chen, Urszula Wojtyra and Cameron Weir.

The decision is noteworthy for several reasons, including its unique and lengthy background, a U.S. connection and the variety of issues raised.

The '693 Patent pertains to a formulation for omeprazole (a proton pump inhibitor used for gastrointestinal disorders) having "an inert subcoating", which has been successfully marketed by AstraZeneca under the brand name LOSEC. 

The '693 Patent was first litigated by AstraZeneca and Apotex in 1993, when it became the subject of one of the earliest proceedings under the Patented Medicines (Notice of Compliance) Regulations (Court File No. T-1446-93). That case was concluded on the basis of a consent dismissal. However, the formulation disclosed by Apotex at that time turned out later to not be the one that was the subject of its regulatory submission. This led AstraZeneca to raise deceit as an issue in the later infringement action. Apotex's reliance on a different formulation also led to a judicial review application by AstraZeneca, dismissed in AstraZeneca Canada Inc v Apotex Inc, 2004 FC 1278; aff'd 2005 FCA 58.

Apotex did not separately apply a subcoating to its omeprazole pellets, but rather its subcoating was formed in situ. Thus, while there was no serious dispute that Apotex's omeprazole pellets contained a subcoating, a key issue was whether Apo-Omeprazole contained an inert subcoating as claimed in the '693 Patent.

Apotex argued that, on a purposive of construction, an "inert subcoating" covered only a subcoating that is physically applied to the pellet core and is wholly free of holes, gaps or structural anomalies. Apotex further argued that a person of skill would interpret "inert" to be a compound that is wholly unreactive with any of the other constituents of the formulation, whether or not there are any functional implications. In contrast, AstraZeneca asserted that the claimed subcoating is not limited to any particular process and need not be perfect. In rejecting Apotex's arguments, Justice Barnes cautioned against the danger of relying too heavily on the disclosure as an interpretive guide for claim language. Notably the claims at issue were not limited to any particular method of manufacture and Justice Barnes found the patentee to be entitled to protect the product regardless of the means of its creation. He also did not agree with Apotex that a person of skill would expect the subcoating to be structurally perfect and completely unreactive within its environment.

Turning to validity, Justice Barnes rejected Apotex's anticipation argument on the basis that the asserted reference (EP 495) did not disclose the use of the subcoating to overcome the stability/gastric acid resistance problem addressed by the '693 Patent. Further, in rejecting Apotex's obviousness arguments, Justice Barnes found that neither the problem faced by AstraZeneca nor its solution was as simple as Apotex suggested. He also cautioned against employing a hindsight analysis, particularly in circumstances where the expert who carries out an obviousness analysis relies on prior art references selected by counsel. He also noted that the recognition that a problem exists can be just as relevant to inventiveness as its solution. Finally, in rejecting Apotex's assertions of overbreadth, inutility and ambiguity, Justice Barnes applied the principle set forth by the Supreme Court of Canada in Burton Parsons Chemicals Inc v Hewlett-Packard (Canada) Ltd, [1976] 1 SCR 555that a patent is not overbroad because it leaves it up to the person of skill to avoid known unsuitable choices.

AstraZeneca and Apotex had already litigated the corresponding U.S. patent in respect of the same Apo-Omeprazole made by Apotex in Canada. The U.S. Court had found the U.S. patent valid and infringed. AstraZeneca relied in the Canadian action on its testing of Apo-Omeprazole in the U.S. litigation and also alleged that Apotex was estopped from disputing certain of the U.S. Court's factual findings on the characteristics of Apo-Omeprazole. AstraZeneca relied on testing of additional batches for the Canadian action.

Justice Barnes found Apotex's Apo-Omeprazole infringed the asserted claims. In so finding, Justice Barnes largely rejected Apotex's criticisms of AstraZeneca's testing expert, Dr. Martyn Davies. He also criticized the limited extent of Apotex's testing and the fact that it was not conducted by Apotex's own experts.  Further, Apotex was found to have induced infringement by its customers and by end-users throughout Canada, by promoting and selling its Apo-Omeprazole product across Canada and by directly comparing its product to LOSEC for the same indications. These findings were relevant to the determination that the applicable limitation period in this case was six years, regardless of the place where the infringing activity took place. 

Justice Barnes declined however to find foreign issue estoppel. While he noted it had "some theoretical appeal", he declined to apply the principle, inter alia, for practical considerations (it would only apply to a handful of findings and it was not necessary to fill an evidentiary gap).

As for remedies, Justice Barnes permitted AstraZeneca to elect an accounting of profits. Further, although he did not grant punitive damages for Apotex having misrepresented its Apo-Omeprazole formulation in the course of the earlier NOC proceedings, he found that the failure in not correcting the mistake at the first available opportunity may bear on the issue of costs, which has been reserved pending further submissions. 

The preceding is intended as a timely update on Canadian intellectual property and technology law. The content is informational only and does not constitute legal or professional advice. To obtain such advice, please communicate with our offices directly.

To print this article, all you need is to be registered on Mondaq.com.

Click to Login as an existing user or Register so you can print this article.

Authors
Mark Biernacki
Similar Articles
Relevancy Powered by MondaqAI
 
In association with
Related Topics
 
Similar Articles
Relevancy Powered by MondaqAI
Related Articles
 
Related Video
Up-coming Events Search
Tools
Print
Font Size:
Translation
Channels
Mondaq on Twitter
 
Register for Access and our Free Biweekly Alert for
This service is completely free. Access 250,000 archived articles from 100+ countries and get a personalised email twice a week covering developments (and yes, our lawyers like to think you’ve read our Disclaimer).
 
Email Address
Company Name
Password
Confirm Password
Position
Mondaq Topics -- Select your Interests
 Accounting
 Anti-trust
 Commercial
 Compliance
 Consumer
 Criminal
 Employment
 Energy
 Environment
 Family
 Finance
 Government
 Healthcare
 Immigration
 Insolvency
 Insurance
 International
 IP
 Law Performance
 Law Practice
 Litigation
 Media & IT
 Privacy
 Real Estate
 Strategy
 Tax
 Technology
 Transport
 Wealth Mgt
Regions
Africa
Asia
Asia Pacific
Australasia
Canada
Caribbean
Europe
European Union
Latin America
Middle East
U.K.
United States
Worldwide Updates
Registration (you must scroll down to set your data preferences)

Mondaq Ltd requires you to register and provide information that personally identifies you, including your content preferences, for three primary purposes (full details of Mondaq’s use of your personal data can be found in our Privacy and Cookies Notice):

  • To allow you to personalize the Mondaq websites you are visiting to show content ("Content") relevant to your interests.
  • To enable features such as password reminder, news alerts, email a colleague, and linking from Mondaq (and its affiliate sites) to your website.
  • To produce demographic feedback for our content providers ("Contributors") who contribute Content for free for your use.

Mondaq hopes that our registered users will support us in maintaining our free to view business model by consenting to our use of your personal data as described below.

Mondaq has a "free to view" business model. Our services are paid for by Contributors in exchange for Mondaq providing them with access to information about who accesses their content. Once personal data is transferred to our Contributors they become a data controller of this personal data. They use it to measure the response that their articles are receiving, as a form of market research. They may also use it to provide Mondaq users with information about their products and services.

Details of each Contributor to which your personal data will be transferred is clearly stated within the Content that you access. For full details of how this Contributor will use your personal data, you should review the Contributor’s own Privacy Notice.

Please indicate your preference below:

Yes, I am happy to support Mondaq in maintaining its free to view business model by agreeing to allow Mondaq to share my personal data with Contributors whose Content I access
No, I do not want Mondaq to share my personal data with Contributors

Also please let us know whether you are happy to receive communications promoting products and services offered by Mondaq:

Yes, I am happy to received promotional communications from Mondaq
No, please do not send me promotional communications from Mondaq
Terms & Conditions

Mondaq.com (the Website) is owned and managed by Mondaq Ltd (Mondaq). Mondaq grants you a non-exclusive, revocable licence to access the Website and associated services, such as the Mondaq News Alerts (Services), subject to and in consideration of your compliance with the following terms and conditions of use (Terms). Your use of the Website and/or Services constitutes your agreement to the Terms. Mondaq may terminate your use of the Website and Services if you are in breach of these Terms or if Mondaq decides to terminate the licence granted hereunder for any reason whatsoever.

Use of www.mondaq.com

To Use Mondaq.com you must be: eighteen (18) years old or over; legally capable of entering into binding contracts; and not in any way prohibited by the applicable law to enter into these Terms in the jurisdiction which you are currently located.

You may use the Website as an unregistered user, however, you are required to register as a user if you wish to read the full text of the Content or to receive the Services.

You may not modify, publish, transmit, transfer or sell, reproduce, create derivative works from, distribute, perform, link, display, or in any way exploit any of the Content, in whole or in part, except as expressly permitted in these Terms or with the prior written consent of Mondaq. You may not use electronic or other means to extract details or information from the Content. Nor shall you extract information about users or Contributors in order to offer them any services or products.

In your use of the Website and/or Services you shall: comply with all applicable laws, regulations, directives and legislations which apply to your Use of the Website and/or Services in whatever country you are physically located including without limitation any and all consumer law, export control laws and regulations; provide to us true, correct and accurate information and promptly inform us in the event that any information that you have provided to us changes or becomes inaccurate; notify Mondaq immediately of any circumstances where you have reason to believe that any Intellectual Property Rights or any other rights of any third party may have been infringed; co-operate with reasonable security or other checks or requests for information made by Mondaq from time to time; and at all times be fully liable for the breach of any of these Terms by a third party using your login details to access the Website and/or Services

however, you shall not: do anything likely to impair, interfere with or damage or cause harm or distress to any persons, or the network; do anything that will infringe any Intellectual Property Rights or other rights of Mondaq or any third party; or use the Website, Services and/or Content otherwise than in accordance with these Terms; use any trade marks or service marks of Mondaq or the Contributors, or do anything which may be seen to take unfair advantage of the reputation and goodwill of Mondaq or the Contributors, or the Website, Services and/or Content.

Mondaq reserves the right, in its sole discretion, to take any action that it deems necessary and appropriate in the event it considers that there is a breach or threatened breach of the Terms.

Mondaq’s Rights and Obligations

Unless otherwise expressly set out to the contrary, nothing in these Terms shall serve to transfer from Mondaq to you, any Intellectual Property Rights owned by and/or licensed to Mondaq and all rights, title and interest in and to such Intellectual Property Rights will remain exclusively with Mondaq and/or its licensors.

Mondaq shall use its reasonable endeavours to make the Website and Services available to you at all times, but we cannot guarantee an uninterrupted and fault free service.

Mondaq reserves the right to make changes to the services and/or the Website or part thereof, from time to time, and we may add, remove, modify and/or vary any elements of features and functionalities of the Website or the services.

Mondaq also reserves the right from time to time to monitor your Use of the Website and/or services.

Disclaimer

The Content is general information only. It is not intended to constitute legal advice or seek to be the complete and comprehensive statement of the law, nor is it intended to address your specific requirements or provide advice on which reliance should be placed. Mondaq and/or its Contributors and other suppliers make no representations about the suitability of the information contained in the Content for any purpose. All Content provided "as is" without warranty of any kind. Mondaq and/or its Contributors and other suppliers hereby exclude and disclaim all representations, warranties or guarantees with regard to the Content, including all implied warranties and conditions of merchantability, fitness for a particular purpose, title and non-infringement. To the maximum extent permitted by law, Mondaq expressly excludes all representations, warranties, obligations, and liabilities arising out of or in connection with all Content. In no event shall Mondaq and/or its respective suppliers be liable for any special, indirect or consequential damages or any damages whatsoever resulting from loss of use, data or profits, whether in an action of contract, negligence or other tortious action, arising out of or in connection with the use of the Content or performance of Mondaq’s Services.

General

Mondaq may alter or amend these Terms by amending them on the Website. By continuing to Use the Services and/or the Website after such amendment, you will be deemed to have accepted any amendment to these Terms.

These Terms shall be governed by and construed in accordance with the laws of England and Wales and you irrevocably submit to the exclusive jurisdiction of the courts of England and Wales to settle any dispute which may arise out of or in connection with these Terms. If you live outside the United Kingdom, English law shall apply only to the extent that English law shall not deprive you of any legal protection accorded in accordance with the law of the place where you are habitually resident ("Local Law"). In the event English law deprives you of any legal protection which is accorded to you under Local Law, then these terms shall be governed by Local Law and any dispute or claim arising out of or in connection with these Terms shall be subject to the non-exclusive jurisdiction of the courts where you are habitually resident.

You may print and keep a copy of these Terms, which form the entire agreement between you and Mondaq and supersede any other communications or advertising in respect of the Service and/or the Website.

No delay in exercising or non-exercise by you and/or Mondaq of any of its rights under or in connection with these Terms shall operate as a waiver or release of each of your or Mondaq’s right. Rather, any such waiver or release must be specifically granted in writing signed by the party granting it.

If any part of these Terms is held unenforceable, that part shall be enforced to the maximum extent permissible so as to give effect to the intent of the parties, and the Terms shall continue in full force and effect.

Mondaq shall not incur any liability to you on account of any loss or damage resulting from any delay or failure to perform all or any part of these Terms if such delay or failure is caused, in whole or in part, by events, occurrences, or causes beyond the control of Mondaq. Such events, occurrences or causes will include, without limitation, acts of God, strikes, lockouts, server and network failure, riots, acts of war, earthquakes, fire and explosions.

By clicking Register you state you have read and agree to our Terms and Conditions